CancerVacs is developing intralymphnode immunotherapeutics for certain metastatic cancer patients with no therapeutic options. This includes disseminated follicular lymphoma, glioblastoma multiforme, metastatic castrate-resistant prostate carcinoma, malignant melanoma, or other metastatic solid tumor.
CancerVacs utilizes a patients’ lymphatic system, especially lymphnodes, as bioreactors that retrain cancer patients’ own immune cells to specifically recognize and kill tumor cells. By directly injecting therapeutic vaccine (DNA, mRNA or Peptide encoded) antigens (including Cancer Testis Antigen epitopes), antibodies, cells and cytokines into patients’ lymph nodes, the company is able to use safe, low doses of immunotherapeutics, preventing systemic toxicities and avoiding unwanted side effects and high costs.
CancerVacs’ ultrasound-guided intralyphnode immunotherapeutics generate cell-mediated anti-tumor immune responses for neoplastic disease control, tumor regression and cancer cures. Intralymphnode immunotherapeutic products are being fully-integrated with metastatic cancer patient standard of care.
Currently, there is no effective treatment or cure for disseminated follicular lymphoma and certain metastatic solid cancers, including melanomas, carcinomas and gliomas.
For more on CancerVacs, visit the company’s website.